Developments in virus-like particle-based vaccines for infectious diseases and cancer

References

• Amanna IJ, Slifka MK. Wanted, dead or alive: new viral vaccines. Antiviral Res.84(2), 119–130 (2009).
   PubMed Web of Science ®Google Scholar
• Furione M, Guillot S, Otelea D, Balanant J, Candrea A, Crainic R. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. Virology196(1), 199–208 (1993).
   PubMed Web of Science ®Google Scholar
• Georgescu MM, Balanant J, Macadam A et al. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis. J. Virol.71(10), 7758–7768 (1997).
   PubMed Web of Science ®Google Scholar
• Nkowane BM, Wassilak SG, Orenstein WA et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA257(10), 1335–1340 (1987).
   PubMed Web of Science ®Google Scholar
• Nathanson N, Langmuir AD. The Cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am. J. Epidemiol.142(2), 109–140 (1995).
   PubMed Web of Science ®Google Scholar
• Fulginiti VA, Eller JJ, Downie AW, Kempe CH. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA202(12), 1075–1080 (1967).
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.89(4), 422–434 (1969).
   PubMed Web of Science ®Google Scholar
• McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature307(5947), 178–180 (1984).
   PubMed Web of Science ®Google Scholar
• Yap I, Guan R, Chan SH. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein – a preliminary study on immunogenicity. Vaccine10(7), 439–442 (1992).
   PubMed Web of Science ®Google Scholar
• Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med.347, 1645–1651 (2002).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA89, 12180–12184 (1992).
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer115(16), 3670–3679 (2009).
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect. Dis.10(5), 305–316 (2010).
   PubMed Web of Science ®Google Scholar
• Aurisicchio L, Ciliberto G. Patented cancer vaccines: the promising leads. Expert Opin. Ther. Pat.20(5), 647–660 (2010).
   PubMed Web of Science ®Google Scholar
• Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J. Clin. Oncol.39(2), 73–80 (2009).
   PubMed Web of Science ®Google Scholar
• Zepp F. Principles of vaccine design-Lessons from nature. Vaccine28(Suppl. 3), C14–C24 (2010).
   PubMed Web of Science ®Google Scholar
• Gheysen D, Jacobs E, de Foresta F et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell59, 103–112 (1989).
   PubMed Web of Science ®Google Scholar
• Delchambre M, Gheysen D, Thines D et al. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J.8(9), 2653–2660 (1989).
   PubMed Web of Science ®Google Scholar
• Miyanohara A, Imamura T, Araki M, Sugawara K, Ohtomo N, Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptides translated from different initiation codons. J. Virol.59, 176–180 (1986).
   PubMed Web of Science ®Google Scholar
• Takamura S, Niikura M, Li TC et al. DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration. Gene Ther.11(7), 628–635 (2004).
   PubMed Web of Science ®Google Scholar
• Malboeuf CM, Simon DA, Lee YE et al. Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine25(17), 3270–3276 (2007).
   PubMed Web of Science ®Google Scholar
• Touze A, Coursaget P. In vitro gene transfer using human papillomavirus-like particles. Nucleic Acids Res.26(5), 1317–1323 (1998).
   PubMed Web of Science ®Google Scholar
• Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev. Vaccines8(10), 1379–1398 (2009).
   PubMed Web of Science ®Google Scholar
• Xu YF, Zhang YQ, Xu XM, Song GX. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes. Arch. Virol.151(11), 2133–2148 (2006).
   PubMedGoogle Scholar
• Blumberg BS, Alter HJ, Visnich S. A ‘new’ antigen in leukemia sera. JAMA191, 541–546 (1965).
   PubMed Web of Science ®Google Scholar
• Brady JN, Consigli RA. Chromatographic separation of the polyoma virus proteins and renaturation of the isolated VP1 major capsid protein. J. Virol.27(2), 436–442 (1978).
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Tornesello ML, Buonaguro FM. Virus-like particles as particulate vaccines. Curr. HIV Res.8(4), 299–309 (2010).
   PubMed Web of Science ®Google Scholar
• Fernandez-San MA, Ortigosa SM, Hervas-Stubbs S et al. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic. Plant Biotechnol. J.6(5), 427–441 (2008).
   PubMed Web of Science ®Google Scholar
• Lopez de Turiso JA, Cortes E, Martinez C et al. Recombinant vaccine for canine parvovirus in dogs. J. Virol.66(5), 2748–2753 (1992).
   PubMedGoogle Scholar
• Brautigam S, Snezhkov E, Bishop DH. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology192(2), 512–524 (1993).
   PubMed Web of Science ®Google Scholar
• Kozlovska TM, Cielens I, Dreilinna D et al. Recombinant RNA phage Q beta capsid particles synthesized and self-assembled in Escherichia coli. Gene137(1), 133–137 (1993).
   PubMedGoogle Scholar
• Peabody DS, Manifold-Wheeler B, Medford A, Jordan SK, do Carmo CJ, Chackerian B. Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. J. Mol. Biol.380(1), 252–263 (2008).
   PubMed Web of Science ®Google Scholar
• French TJ, Roy P. Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV. J. Virol.64(4), 1530–1536 (1990).
   PubMed Web of Science ®Google Scholar
• Yamshchikov GV, Ritter GD, Vey M, Compans RW. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology214, 50–58 (1995).
   PubMed Web of Science ®Google Scholar
• Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol.72, 3827–3836 (1998).
   PubMed Web of Science ®Google Scholar
• Kang SM, Song JM, Quan FS, Compans RW. Influenza vaccines based on virus-like particles. Virus Res.143(2), 140–146 (2009).
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Buonaguro FM, Tornesello ML et al. High efficient production of Pr55gag virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res.49, 35–47 (2001).
   PubMed Web of Science ®Google Scholar
• Wagner R, Deml L, Fliessbach H, Wanner G, Wolf H. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology200, 162–175 (1994).
   PubMedGoogle Scholar
• Deml L, Kratochwil G, Osterrieder N, Knuchel R, Wolf H, Wagner R. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein–Barr virus gp220/350-derived transmembrane domain. Virology235, 10–25 (1997).
   PubMedGoogle Scholar
• Crooks ET, Moore PL, Franti M et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology366(2), 245–262 (2007).
   PubMed Web of Science ®Google Scholar
• Wang BZ, Liu W, Kang SM et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J. Virol.81(20), 10869–10878 (2007).
   PubMedGoogle Scholar
• Tobin GJ, Li GH, Fong SE, Nagashima K, Gonda MA. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit gag- and SU-specific murine cytotoxic T-lymphocyte activities. Virology236, 307–315 (1997).
   PubMedGoogle Scholar
• Griffiths JC, Harris SJ, Layton GT et al. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag:V3 fusion. J. Virol.67, 3191–3198 (1993).
   PubMed Web of Science ®Google Scholar
• Dale CJ, Liu XS, De Rose R et al. Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology301, 176–187 (2002).
   PubMed Web of Science ®Google Scholar
• Weber J, Cheinsong-Popov R, Callow D et al. Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles (p24-VLP) in healthy volunteers. Vaccine13(9), 831–834 (1995).
   PubMed Web of Science ®Google Scholar
• Ulrich R, Nassal M, Meisel H, Kruger DH. Core particles of hepatitis B virus as carrier for foreign epitopes. Adv. Virus Res.50, 141–182 (1998).
   PubMed Web of Science ®Google Scholar
• Kratz PA, Bottcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc. Natl Acad. Sci. USA96(5), 1915–1920 (1999).
   PubMed Web of Science ®Google Scholar
• Halsey RJ, Tanzer FL, Meyers A et al. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles. Virus Res.133(2), 259–268 (2008).
   PubMed Web of Science ®Google Scholar
• Schmitz N, Dietmeier K, Bauer M et al. Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J. Exp. Med.206(9), 1941–1955 (2009).
   PubMed Web of Science ®Google Scholar
• Moron VG, Rueda P, Sedlik C, Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J. Immunol.171, 2242–2250 (2003).
   PubMed Web of Science ®Google Scholar
• Moron G, Rueda P, Casal I, Leclerc C. CD8α- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8α and CD205 molecules. J. Exp. Med.195(10), 1233–1245 (2002).
   PubMed Web of Science ®Google Scholar
• Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol.82(5), 506–516 (2004).
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Tornesello ML, Tagliamonte M et al. Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol.80, 9134–9143 (2006).
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM. Th2 polarization in peripheral blood mononuclear cells from human immunodeficiency virus (HIV)-infected subjects, as activated by HIV virus-like particles. J. Virol.83(1), 304–313 (2009).
   PubMed Web of Science ®Google Scholar
• Tsunetsugu-Yokota Y, Morikawa Y, Isogai M et al. Yeast-derived human immunodeficiency virus type 1 p55gag virus-like particles activate dendritic cells (DCs) and induce perforin expression in gag-specific CD8+ T cells by cross-presentation of DCs. J. Virol.77, 10250–10259 (2003).
   PubMed Web of Science ®Google Scholar
• Fausch SC, Da Silva DM, Kast WM. Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells. Cancer Res.63, 3478–3482 (2003).
   PubMed Web of Science ®Google Scholar
• Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin. Immunol.106, 231–237 (2003).
   PubMed Web of Science ®Google Scholar
• Sailaja G, Skountzou I, Quan FS, Compans RW, Kang SM. Human immunodeficiency virus-like particles activate multiple types of immune cells. Virology362(2), 331–341 (2007).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Kundig TM, Kalberer CP, Hengartner H, Zinkernagel RM. Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses. J. Virol.67(7), 3917–3922 (1993).
   PubMed Web of Science ®Google Scholar
• Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething MJ, Braciale VL. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol. Rev.98, 95–114 (1987).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Lutz MB, Layton GT et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur. J. Immunol.26(11), 2595–2600 (1996).
   PubMed Web of Science ®Google Scholar
• Ruedl C, Schwarz K, Jegerlehner A, Storni T, Manolova V, Bachmann MF. Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J. Virol.79(2), 717–724 (2005).
   PubMed Web of Science ®Google Scholar
• Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur. J. Immunol.32(3), 818–825 (2002).
   PubMed Web of Science ®Google Scholar
• Paliard X, Liu Y, Wagner R, Wolf H, Baenzinger J, Walker CM. Priming of strong, broad, and long-lived HIV type 1 p55gag- specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses16, 273–282 (2000).
   PubMed Web of Science ®Google Scholar
• Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl Acad. Sci. USA100(11), 6753–6758 (2003).
   PubMed Web of Science ®Google Scholar
• Schirmbeck R, Bohm W, Reimann J. Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology39(1–2), 111–119 (1996).
   PubMedGoogle Scholar
• Buonaguro L, Racioppi L, Tornesello ML et al. Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antiviral Res.54, 189–201 (2002).
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol.79, 7059–7067 (2005).
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Devito C, Tornesello ML et al. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine25(32), 5968–5977 (2007).
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol.38(5), 1404–1413 (2008).
   PubMed Web of Science ®Google Scholar
• Hinton HJ, Jegerlehner A, Bachmann MF. Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr. Top. Microbiol. Immunol.319, 1–15 (2008).
   PubMedGoogle Scholar
• Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science262(5138), 1448–1451 (1993).
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu. Rev. Immunol.15, 235–270 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang S, Cubas R, Li M, Chen C, Yao Q. Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells. Mol. Immunol.46(10), 1988–2001 (2009).
   PubMedGoogle Scholar
• Aricò E, Wang E, Tornesello ML et al. Immature monocyte derived dendritic cells gene expression profile in response to virus-like particles stimulation. J. Transl. Med.3, 45 (2005).
   PubMed Web of Science ®Google Scholar
• Buonaguro L, Monaco A, Arico E et al. Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics9(Suppl. 2), S5 (2008).
   PubMed Web of Science ®Google Scholar
• Monaco A, Marincola FM, Sabatino M et al. Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett.583(18), 3004–3008 (2009).
   PubMed Web of Science ®Google Scholar
• Frank I, Piatak M Jr, Stoessel H et al. Infectious and whole inactivated simian immunodeficiency viruses interact similarly with primate dendritic cells (DCs): differential intracellular fate of virions in mature and immature DCs. J. Virol.76(6), 2936–2951 (2002).
   PubMedGoogle Scholar
• Bosio CM, Moore BD, Warfield KL et al. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology326(2), 280–287 (2004).
   PubMed Web of Science ®Google Scholar
• Yang R, Martinez Murillo F, Cui H et al. Papillomavirus-Like Particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J. Virol.78, 11152–11160 (2004).
   PubMed Web of Science ®Google Scholar
• Freer G, Matteucci D. Influence of dendritic cells on viral pathogenicity. PLoS.Pathog.5(7), e1000384 (2009).
   Google Scholar
• Sevilla N, McGavern DB, Teng C, Kunz S, Oldstone MB. Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion. J. Clin. Invest.113(5), 737–745 (2004).
   PubMedGoogle Scholar
• Hodges A, Sharrocks K, Edelmann M et al. Activation of the lectin DC-SIGN induces an immature dendritic cell phenotype triggering Rho-GTPase activity required for HIV-1 replication. Nat. Immunol.8(6), 569–577 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez PA, Prado CE, Leiva ED et al. Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells. Proc. Natl Acad. Sci. USA105(39), 14999–15004 (2008).
   PubMed Web of Science ®Google Scholar
• Saito K, Ait-Goughoulte M, Truscott SM et al. Hepatitis C virus inhibits cell surface expression of HLA-DR, prevents dendritic cell maturation, and induces interleukin-10 production. J. Virol.82(7), 3320–3328 (2008).
   PubMedGoogle Scholar
• Takeuchi O, Akira S. Recognition of viruses by innate immunity. Immunol. Rev.220, 214–224 (2007).
   PubMed Web of Science ®Google Scholar
• Storni T, Lechner F, Erdmann I et al. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J. Immunol.168(6), 2880–2886 (2002).
   PubMedGoogle Scholar
• Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J. Immunol.172(3), 1777–1785 (2004).
   PubMed Web of Science ®Google Scholar
• Skountzou I, Quan FS, Gangadhara S et al. Incorporation of glycosylphosphatidylinositol-anchored granulocyte-macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles. J. Virol.81(3), 1083–1094 (2007).
   PubMed Web of Science ®Google Scholar
• Wang BZ, Quan FS, Kang SM, Bozja J, Skountzou I, Compans RW. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol.82(23), 11813–11823 (2008).
   PubMed Web of Science ®Google Scholar
• Schwarz K, Storni T, Manolova V et al. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol.33(6), 1465–1470 (2003).
   PubMedGoogle Scholar
• Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets6(4), 223–235 (2007).
   PubMedGoogle Scholar
• Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA218(11), 1665–1670 (1971).
   PubMed Web of Science ®Google Scholar
• Bayer ME, Blumberg BS, Werner B. Particles associated with Australia antigen in the sera of patients with leukaemia, Down’s Syndrome and hepatitis. Nature218(5146), 1057–1059 (1968).
   PubMed Web of Science ®Google Scholar
• Wampler DE, Lehman ED, Boger J, McAleer WJ, Scolnick EM. Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proc. Natl Acad. Sci. USA82(20), 6830–6834 (1985).
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature298(5872), 347–350 (1982).
   PubMed Web of Science ®Google Scholar
• Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N. Engl. J. Med.336(26), 1855–1859 (1997).
   PubMed Web of Science ®Google Scholar
• Wichajarn K, Kosalaraksa P, Wiangnon S. Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program. Asian Pac. J. Cancer Prev.9(3), 507–509 (2008).
   PubMedGoogle Scholar
• Lanier AP, Holck P, Ehrsam DG, Key C. Childhood cancer among Alaska Natives. Pediatrics112(5), e396 (2003).
   Google Scholar
• Huang Z, Elkin G, Maloney BJ et al. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine23(15), 1851–1858 (2005).
   PubMed Web of Science ®Google Scholar
• Pniewski T, Kapusta J, Bociag P et al. Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation. J. Appl. Genet.52(2), 125–136 (2011).
   PubMed Web of Science ®Google Scholar
• Huang Z, Chen Q, Hjelm B, Arntzen C, Mason H. A DNA replicon system for rapid high-level production of virus-like particles in plants. Biotechnol. Bioeng.103(4), 706–714 (2009).
   PubMed Web of Science ®Google Scholar
• Nardin EH, Oliveira GA, Calvo-Calle JM et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect. Immun.72(11), 6519–6527 (2004).
   PubMed Web of Science ®Google Scholar
• Stahl SJ, Murray K. Immunogenicity of peptide fusions to hepatitis B virus core antigen. Proc. Natl Acad. Sci. USA86(16), 6283–6287 (1989).
   PubMed Web of Science ®Google Scholar
• Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology44(2–3), 98–114 (2001).
   PubMed Web of Science ®Google Scholar
• Mihailova M, Boos M, Petrovskis I et al. Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine24(20), 4369–4377 (2006).
   PubMed Web of Science ®Google Scholar
• Kazaks A, Balmaks R, Voronkova T, Ose V, Pumpens P. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope. Biotechnol. J.3(11), 1429–1436 (2008).
   PubMedGoogle Scholar
• Geldmacher A, Skrastina D, Borisova G et al. A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies. Vaccine23(30), 3973–3983 (2005).
   PubMed Web of Science ®Google Scholar
• Walker A, Skamel C, Vorreiter J, Nassal M. Internal core protein cleavage leaves the hepatitis B virus capsid intact and enhances its capacity for surface display of heterologous whole chain proteins. J. Biol. Chem.283(48), 33508–33515 (2008).
   PubMed Web of Science ®Google Scholar
• Nassal M, Skamel C, Vogel M et al. Development of hepatitis B virus capsids into a whole-chain protein antigen display platform: new particulate Lyme disease vaccines. Int. J. Med. Microbiol.298(1–2), 135–142 (2008).
   PubMedGoogle Scholar
• Maclean J, Koekemoer M, Olivier AJ et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J. Gen. Virol.88(Pt 5), 1460–1469 (2007).
   PubMed Web of Science ®Google Scholar
• Sasagawa T, Pushko P, Steers G et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology206(1), 126–135 (1995).
   PubMed Web of Science ®Google Scholar
• Lenzi P, Scotti N, Alagna F et al. Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Res.17(6), 1091–1102 (2008).
   PubMedGoogle Scholar
• Christensen ND, Reed CA, Cladel NM, Han R, Kreider JW. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol.70(2), 960–965 (1996).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Chandrachud LM, O’Neil BW et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology219(1), 37–44 (1996).
   PubMed Web of Science ®Google Scholar
• Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA92(25), 11553–11557 (1995).
   PubMed Web of Science ®Google Scholar
• Zhang LF, Zhou J, Chen S et al. HPV6b virus like particles are potent immunogens without adjuvant in man. Vaccine18(11–12), 1051–1058 (2000).
   PubMed Web of Science ®Google Scholar
• Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol.73(11), 9063–9071 (1999).
   PubMed Web of Science ®Google Scholar
• Brown DR, Bryan JT, Schroeder JM et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J. Infect. Dis.184(9), 1183–1186 (2001).
   PubMed Web of Science ®Google Scholar
• Evans TG, Bonnez W, Rose RC et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis.183(10), 1485–1493 (2001).
   PubMed Web of Science ®Google Scholar
• Harro CD, Pang YY, Roden RB et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl Cancer Inst.93(4), 284–292 (2001).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet369(9580), 2161–2170 (2007).
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95(11), 1459–1466 (2006).
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356(19), 1915–1927 (2007).
   PubMed Web of Science ®Google Scholar
• Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Olsson SE, Villa LL, Costa RL et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine25(26), 4931–4939 (2007).
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet374(9686), 301–314 (2009).
   PubMed Web of Science ®Google Scholar
• Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet369(9576), 1861–1868 (2007).
   PubMed Web of Science ®Google Scholar
• Munoz N, Kjaer SK, Sigurdsson K et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl Cancer Inst.102(5), 325–339 (2010).
   PubMed Web of Science ®Google Scholar
• Roden RB, Yutzy WH, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology270(2), 254–257 (2000).
   PubMed Web of Science ®Google Scholar
• Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J. Virol.76(19), 9798–9805 (2002).
   PubMed Web of Science ®Google Scholar
• Gambhira R, Karanam B, Jagu S et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J. Virol.81(24), 13927–13931 (2007).
   PubMedGoogle Scholar
• Gambhira R, Jagu S, Karanam B et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J. Virol.81(21), 11585–11592 (2007).
   PubMed Web of Science ®Google Scholar
• Pastrana DV, Gambhira R, Buck CB et al. Cross-neutralization of cutaneous and mucosal papillomavirus types with anti-sera to the amino terminus of L2. Virology337(2), 365–372 (2005).
   PubMed Web of Science ®Google Scholar
• Varsani A, Williamson AL, de Villiers D, Becker I, Christensen ND, Rybicki EP. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16. J. Virol.77(15), 8386–8393 (2003).
   PubMed Web of Science ®Google Scholar
• Kawana K, Yasugi T, Kanda T et al. Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine21(27–30), 4256–4260 (2003).
   PubMed Web of Science ®Google Scholar
• Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1–L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J. Virol.83(19), 10085–10095 (2009).
   PubMed Web of Science ®Google Scholar
• Slupetzky K, Gambhira R, Culp TD et al. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine25(11), 2001–2010 (2007).
   PubMed Web of Science ®Google Scholar
• Caldeira JC, Medford A, Kines RC et al. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine28(27), 4384–4393 (2010).
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J. Virol.66(11), 6527–6532 (1992).
   PubMed Web of Science ®Google Scholar
• Santi L, Batchelor L, Huang Z et al. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine26(15), 1846–1854 (2008).
   PubMed Web of Science ®Google Scholar
• Ball JM, Hardy ME, Atmar RL, Conner ME, Estes MK. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice. J. Virol.72(2), 1345–1353 (1998).
   PubMed Web of Science ®Google Scholar
• Guerrero RA, Ball JM, Krater SS, Pacheco SE, Clements JD, Estes MK. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosa (fecal and vaginal) immune responses. J. Virol.75, 9713–9722 (2001).
   PubMedGoogle Scholar
• Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl Acad. Sci. USA93(11), 5335–5340 (1996).
   PubMed Web of Science ®Google Scholar
• Zhang X, Buehner NA, Hutson AM, Estes MK, Mason HS. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein. Plant Biotechnol. J.4(4), 419–432 (2006).
   PubMed Web of Science ®Google Scholar
• Velasquez LS, Shira S, Berta AN et al. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine. Vaccine29(32), 5221–5231 (2011).
   PubMed Web of Science ®Google Scholar
• Velasquez LS, Hjelm BE, Arntzen CJ, Herbst-Kralovetz MM. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin. Vaccine Immunol.17(12), 1850–1858 (2010).
   PubMed Web of Science ®Google Scholar
• Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, Estes MK. Recombinant Norwalk virus-like particles given orally to volunteers: Phase I study. Gastroenterology117(1), 40–48 (1999).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Sztein MB, Losonsky GA, Wasserman SS, Estes MK. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin. Immunol.108(3), 241–247 (2003).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis.182(1), 302–305 (2000).
   PubMed Web of Science ®Google Scholar
• Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol.75(13), 6154–6165 (2001).
   PubMed Web of Science ®Google Scholar
• Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine23(50), 5751–5759 (2005).
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine25(19), 3871–3878 (2007).
   PubMed Web of Science ®Google Scholar
• Quan FS, Huang C, Compans RW, Kang SM. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol.81(7), 3514–3524 (2007).
   PubMed Web of Science ®Google Scholar
• Matassov D, Cupo A, Galarza JM. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol.20(3), 441–452 (2007).
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Crevar CJ et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One.3(1), e1501 (2008).
   PubMed Web of Science ®Google Scholar
• Mahmood K, Bright RA, Mytle N et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine26(42), 5393–5399 (2008).
   PubMed Web of Science ®Google Scholar
• Guo L, Lu X, Kang SM, Chen C, Compans RW, Yao Q. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology313(2), 502–513 (2003).
   PubMed Web of Science ®Google Scholar
• Szecsi J, Boson B, Johnsson P et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol. J.3, 70 (2006).
   PubMed Web of Science ®Google Scholar
• Haynes JR, Dokken L, Wiley JA et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine27(4), 530–541 (2009).
   PubMed Web of Science ®Google Scholar
• Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol.18(1), 244–251 (2005).
   PubMed Web of Science ®Google Scholar
• Koletzki D, Lundkvist A, Sjolander KB et al. Puumala (PUU) hantavirus strain differences and insertion positions in the hepatitis B virus core antigen influence B-cell immunogenicity and protective potential of core-derived particles. Virology276(2), 364–375 (2000).
   PubMed Web of Science ®Google Scholar
• De FM, Martens W, Smet A et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine26(51), 6503–6507 (2008).
   PubMedGoogle Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med.5(10), 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar
• Pumpens P, Razanskas R, Pushko P et al. Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology45(1), 24–32 (2002).
   PubMed Web of Science ®Google Scholar
• Bisht H, Chugh DA, Raje M, Swaminathan SS, Khanna N. Recombinant dengue virus type 2 envelope/hepatitis B surface antigen hybrid protein expressed in Pichia pastoris can function as a bivalent immunogen. J. Biotechnol.99(2), 97–110 (2002).
   PubMedGoogle Scholar
• Eckhart L, Raffelsberger W, Ferko B et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol.77( Pt 9), 2001–2008 (1996).
   PubMed Web of Science ®Google Scholar
• Schlienger K, Mancini M, Riviere Y, Dormont D, Tiollais P, Michel ML. Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates. J. Virol.66(4), 2570–2576 (1992).
   PubMedGoogle Scholar
• Netter HJ, Macnaughton TB, Woo WP, Tindle R, Gowans EJ. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J. Virol.75(5), 2130–2141 (2001).
   PubMed Web of Science ®Google Scholar
• Woo WP, Doan T, Herd KA, Netter HJ, Tindle RW. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J. Virol.80(8), 975–3984 (2006).
   PubMedGoogle Scholar
• Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol.169(11), 6120–6126 (2002).
   PubMed Web of Science ®Google Scholar
• Maurer P, Jennings GT, Willers J et al. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur. J. Immunol.35(7), 2031–2040 (2005).
   PubMed Web of Science ®Google Scholar
• Cornuz J, Zwahlen S, Jungi WF et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One3(6), e2547 (2008).
   PubMed Web of Science ®Google Scholar
• Ambuhl PM, Tissot AC, Fulurija A et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and Phase I safety and immunogenicity. J. Hypertens.25(1), 63–72 (2007).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Rangel M, Hunter Z, Peabody DS. Virus and virus-like particle-based immunogens for Alzheimer’s disease induce antibody responses against amyloid-β without concomitant T cell responses. Vaccine24(37–39), 6321–6331 (2006).
   PubMed Web of Science ®Google Scholar
• Spohn G, Keller I, Beck M, Grest P, Jennings GT, Bachmann MF. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol.38(3), 877–887 (2008).
   PubMed Web of Science ®Google Scholar
• Fiers W, De Filette M, El Bakkouri K et al. M2e-based universal influenza A vaccine. Vaccine27(45), 6280–6283 (2009).
   PubMed Web of Science ®Google Scholar
• Peters BS, Cheingsong-Popov R, Callow D et al. A pilot Phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. J. Infect.35, 231–235 (1997).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Bakare N, Lori F. Therapeutic vaccination for future management of HIV/AIDS. Vaccine21(7–8), 620–623 (2003).
   PubMed Web of Science ®Google Scholar
• Smith D, Gow I, Colebunders R et al. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med.2(4), 272–275 (2001).
   PubMedGoogle Scholar
• Schodel F, Wirtz R, Peterson D et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J. Exp. Med.180(3), 1037–1046 (1994).
   PubMed Web of Science ®Google Scholar
• Oliveira GA, Wetzel K, Calvo-Calle JM et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a Phase I trial. Infect. Immun.73(6), 3587–3597 (2005).
   PubMed Web of Science ®Google Scholar
• Aide P, Dobano C, Sacarlal J et al. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine29(35), 6059–6067 (2011).
   PubMed Web of Science ®Google Scholar
• French TJ, Marshall JJ, Roy P. Assembly of double-shelled, viruslike particles of bluetongue virus by the simultaneous expression of four structural proteins. J. Virol.64(12), 5695–5700 (1990).
   PubMed Web of Science ®Google Scholar
• Belyaev AS, Roy P. Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells. Nucleic Acids Res.21(5), 1219–1223 (1993).
   PubMed Web of Science ®Google Scholar
• Roy P, Bishop DH, LeBlois H, Erasmus BJ. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine12(9), 805–811 (1994).
   PubMed Web of Science ®Google Scholar
• Estes MK, Mason BB, Crawford S, Cohen J. Cloning and nucleotide sequence of the simian rotavirus gene 6 that codes for the major inner capsid protein. Nucleic Acids Res.12(4), 1875–1887 (1984).
   PubMedGoogle Scholar
• Crawford SE, Labbe M, Cohen J, Burroughs MH, Zhou YJ, Estes MK. Characterization of virus-like particles produced by the expression of rotavirus capsid proteins in insect cells. J. Virol.68(9), 5945–5952 (1994).
   PubMed Web of Science ®Google Scholar
• Ready KF, Sabara M. In vitro assembly of bovine rotavirus nucleocapsid protein. Virology157(1), 189–198 (1987).
   PubMedGoogle Scholar
• Agnello D, Herve CA, Lavaux A et al. Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice. J. Virol.80(8), 3823–3832 (2006).
   PubMed Web of Science ®Google Scholar
• O’Neal CM, Crawford SE, Estes MK, Conner ME. Rotavirus virus-like particles administered mucosally induce protective immunity. J. Virol.71, 8707–8717 (1997).
   PubMed Web of Science ®Google Scholar
• Parez N, Fourgeux C, Mohamed A et al. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection. J. Virol.80(4), 1752–1761 (2006).
   PubMed Web of Science ®Google Scholar
• Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK. Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine21(25–26), 3885–3900 (2003).
   PubMed Web of Science ®Google Scholar
• Ciarlet M, Crawford SE, Barone C et al. Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity. J. Virol.72, 9233–9246 (1998).
   PubMedGoogle Scholar
• Choi AH, McNeal MM, Flint JA et al. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine20, 1733–1740 (2002).
   PubMed Web of Science ®Google Scholar
• VanCott JL, Prada AE, McNeal MM et al. Mice develop effective but delayed protective immune responses when immunized as neonates either intranasally with nonliving VP6/LT(R192G) or orally with live rhesus rotavirus vaccine candidates. J. Virol.80(10), 4949–4961 (2006).
   PubMed Web of Science ®Google Scholar
• Baumert TF, Vergalla J, Satoi J et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology117(6), 1397–1407 (1999).
   PubMed Web of Science ®Google Scholar
• Elmowalid GA, Qiao M, Jeong SH et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA104(20), 8427–8432 (2007).
   PubMed Web of Science ®Google Scholar
• Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology34(2), 417–423 (2001).
   PubMed Web of Science ®Google Scholar
• Campbell S, Rein A. In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain. J. Virol.73, 2270–2279 (1999).
   PubMed Web of Science ®Google Scholar
• Campbell S, Vogt VM. Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J. Virol.69, 6487–6497 (1995).
   PubMedGoogle Scholar
• Wagner R, Deml L, Schirmbeck R, Niedrig M, Reimann J, Wolf H. Construction, expression and immunogenicity of chimeric HIV-1 virus-like particles. Virology220, 128–140 (1996).
   PubMed Web of Science ®Google Scholar
• Hammonds J, Chen X, Fouts T, Devico A, Montefiori D, Spearman P. Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization. J. Virol.79(23), 14804–14814 (2005).
   PubMed Web of Science ®Google Scholar
• Tagliamonte M, Visciano ML, Tornesello ML, De Stradis A, Buonaguro FM, Buonaguro L. HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine29(31), 4913–4922 (2011).
   PubMed Web of Science ®Google Scholar
• Visciano ML, Diomede L, Tagliamonte M et al. Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine29(31), 4903–4912 (2011).
   PubMed Web of Science ®Google Scholar
• Luo L, Li Y, Cannon PM, Kim S, Kang CY. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc. Natl Acad. Sci. USA89(21), 10527–10531 (1992).
   PubMedGoogle Scholar
• Kim M, Qiao Z, Yu J, Montefiori D, Reinherz EL. Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine25(27), 5102–5114 (2007).
   PubMed Web of Science ®Google Scholar
• Haffar OK, Smithgall MD, Moran PA, Travis BM, Zarling JM, Hu SL. HIV-specific humoral and cellular immunity in rabbits vaccinated with recombinant human immunodeficiency virus-like Gag–Env particles. Virology183, 487–495 (1991).
   PubMed Web of Science ®Google Scholar
• Rovinski B, Haynes JR, Cao SX et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J. Virol.66, 4003–4012 (1992).
   PubMedGoogle Scholar
• Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Virology235, 26–39 (1997).
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Safrit JT, Lydy SL et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J. Virol.75, 5879–5890 (2001).
   PubMed Web of Science ®Google Scholar
• Vassilieva EV, Wang BZ, Vzorov AN et al. Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio2(1), (2011).
   PubMedGoogle Scholar
• Jain S, Patrick AJ, Rosenthal KL. Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen. Vaccine28(43), 7070–7080 (2010).
   PubMed Web of Science ®Google Scholar
• McBurney SP, Ross TM. Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine27(32), 4337–4349 (2009).
   PubMed Web of Science ®Google Scholar
• McBurney SP, Young KR, Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology358(2), 334–346 (2007).
   PubMed Web of Science ®Google Scholar
• Quan FS, Sailaja G, Skountzou I et al. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins. Vaccine25(19), 3841–3850 (2007).
   PubMedGoogle Scholar
• Walker LM, Phogat SK, Chan-Hui PY et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science326(5950), 285–289 (2009).
   PubMed Web of Science ®Google Scholar
• Scheid JF, Mouquet H, Feldhahn N et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature458(7238), 636–640 (2009).
   PubMed Web of Science ®Google Scholar
• Tagliamonte M, Visciano ML, Tornesello ML, De SA, Buonaguro FM, Buonaguro L. Constitutive expression of HIV-VLPs in stably transfected insect cell line for efficient delivery system. Vaccine28(39), 6417–6424 (2010).
   PubMed Web of Science ®Google Scholar
• Choi AH, McNeal MM, Basu M et al. Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses. Vaccine20, 3310–3321 (2002).
   PubMedGoogle Scholar
• Crevar CJ, Ross TM. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol. J.5, 131 (2008).
   PubMed Web of Science ®Google Scholar
• Kang SM, Yoo DG, Lipatov AS et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One4(3), e4667 (2009).
   PubMed Web of Science ®Google Scholar
• Quan FS, Vunnava A, Compans RW, Kang SM. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One5(2), e9161 (2010).
   PubMed Web of Science ®Google Scholar
• Rovinski B, Rodrigues L, Cao SX et al. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins. AIDS Res. Hum. Retroviruses11, 1187–1195 (1995).
   PubMed Web of Science ®Google Scholar
• Liu WJ, Liu XS, Zhao KN, Leggatt GR, Frazer IH. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology273(2), 374–382 (2000).
   PubMed Web of Science ®Google Scholar
• Zamora E, Handisurya A, Shafti-Keramat S et al. Papillomavirus-like particles are an effective platform for amyloid-β immunization in rabbits and transgenic mice. J. Immunol.177(4), 2662–2670 (2006).
   PubMed Web of Science ®Google Scholar
• Vietheer PT, Boo I, Drummer HE, Netter HJ. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antivir. Ther.12(4), 477–487 (2007).
   PubMedGoogle Scholar
• Sadeyen JR, Tourne S, Shkreli M, Sizaret PY, Coursaget P. Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology309(1), 32–40 (2003).
   PubMed Web of Science ®Google Scholar
• Paz De la Rosa G, Monroy-Garcia A, Mora-Garcia ML et al. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice. Virol. J.6, 2 (2009).
   PubMedGoogle Scholar
• Oh YK, Sohn T, Park JS et al. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. Virology328(2), 266–273 (2004).
   PubMedGoogle Scholar
• Krammer F, Schinko T, Messner P, Palmberger D, Ferko B, Grabherr R. Influenza virus-like particles as an antigen-carrier platform for the ESAT-6 epitope of Mycobacterium tuberculosis. J. Virol. Methods167(1), 17–22 (2010).
   PubMed Web of Science ®Google Scholar
• Inoue T, Kawano MA, Takahashi RU et al. Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3. J. Biotechnol.134(1–2), 181–192 (2008).
   PubMed Web of Science ®Google Scholar
• Takahashi RU, Kanesashi SN, Inoue T et al. Presentation of functional foreign peptides on the surface of SV40 virus-like particles. J. Biotechnol.135(4), 385–392 (2008).
   PubMed Web of Science ®Google Scholar